RU2015142437A - Новые связывающие белки для pcsk9 - Google Patents
Новые связывающие белки для pcsk9 Download PDFInfo
- Publication number
- RU2015142437A RU2015142437A RU2015142437A RU2015142437A RU2015142437A RU 2015142437 A RU2015142437 A RU 2015142437A RU 2015142437 A RU2015142437 A RU 2015142437A RU 2015142437 A RU2015142437 A RU 2015142437A RU 2015142437 A RU2015142437 A RU 2015142437A
- Authority
- RU
- Russia
- Prior art keywords
- mutein
- glu
- leu
- ser
- lipocalin
- Prior art date
Links
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 title claims 24
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 title claims 20
- 102000014914 Carrier Proteins Human genes 0.000 title claims 2
- 108091008324 binding proteins Proteins 0.000 title claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 35
- 235000001014 amino acid Nutrition 0.000 claims 25
- 102000019298 Lipocalin Human genes 0.000 claims 24
- 108050006654 Lipocalin Proteins 0.000 claims 24
- 238000006467 substitution reaction Methods 0.000 claims 24
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 claims 23
- 102000048236 human LCN1 Human genes 0.000 claims 23
- 239000012634 fragment Substances 0.000 claims 20
- 239000012530 fluid Substances 0.000 claims 15
- 238000010494 dissociation reaction Methods 0.000 claims 6
- 230000005593 dissociations Effects 0.000 claims 6
- 230000002163 immunogen Effects 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 102000053786 human PCSK9 Human genes 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 238000002703 mutagenesis Methods 0.000 claims 2
- 231100000350 mutagenesis Toxicity 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 101100060131 Mus musculus Cdk5rap2 gene Proteins 0.000 claims 1
- 101100135848 Mus musculus Pcsk9 gene Proteins 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361781511P | 2013-03-14 | 2013-03-14 | |
| US61/781,511 | 2013-03-14 | ||
| EP13175023 | 2013-07-04 | ||
| EP13175023.4 | 2013-07-04 | ||
| PCT/EP2014/055013 WO2014140210A1 (en) | 2013-03-14 | 2014-03-13 | Novel binding proteins for pcsk9 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015142437A true RU2015142437A (ru) | 2017-04-27 |
Family
ID=48703321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015142437A RU2015142437A (ru) | 2013-03-14 | 2014-03-13 | Новые связывающие белки для pcsk9 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9150629B2 (enExample) |
| EP (1) | EP2968490A1 (enExample) |
| JP (1) | JP6619650B2 (enExample) |
| KR (1) | KR20150131151A (enExample) |
| CN (1) | CN105246503A (enExample) |
| AU (1) | AU2014230460B2 (enExample) |
| BR (1) | BR112015021681A2 (enExample) |
| CA (1) | CA2905186A1 (enExample) |
| HK (1) | HK1213194A1 (enExample) |
| IL (1) | IL241329A0 (enExample) |
| MX (1) | MX2015012420A (enExample) |
| PH (1) | PH12015501687A1 (enExample) |
| RU (1) | RU2015142437A (enExample) |
| SG (1) | SG11201505856TA (enExample) |
| WO (1) | WO2014140210A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| WO2014140210A1 (en) | 2013-03-14 | 2014-09-18 | Pieris Ag | Novel binding proteins for pcsk9 |
| WO2015095553A1 (en) * | 2013-12-20 | 2015-06-25 | Nephrogenesis, Llc | Methods and apparatus for kidney dialysis |
| US9398085B2 (en) | 2014-11-07 | 2016-07-19 | Ringcentral, Inc. | Systems and methods for initiating a peer-to-peer communication session |
| DK3292137T3 (da) | 2015-05-04 | 2022-10-17 | Pieris Pharmaceuticals Gmbh | Proteiner specifikke for cd137 |
| IL278710B2 (en) | 2018-05-16 | 2025-09-01 | Lib Therapeutics Llc | Compositions comprising pcsk9 binding compounds and methods of use |
| EP3810176B1 (en) | 2018-06-21 | 2024-12-11 | Ra Pharmaceuticals, Inc. | Cyclic polypeptides for pcsk9 inhibition |
| WO2019246387A1 (en) | 2018-06-21 | 2019-12-26 | Ra Pharmaceuticals, Inc. | Cyclic peptides for pcsk9 inhibition |
| JOP20190150A1 (ar) * | 2018-06-21 | 2019-12-21 | Merck Sharp & Dohme | مركبات مناهضة لـ pcsk9 |
| EP4470609A3 (en) | 2019-01-18 | 2025-03-12 | Astrazeneca AB | Pcsk9 inhibitors and methods of use thereof |
| CA3127973A1 (en) * | 2019-03-29 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| CN114981288B (zh) * | 2020-07-27 | 2024-05-03 | 深圳华大生命科学研究院 | 一种抗体结合的特征性表位及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| NZ508249A (en) | 1998-06-08 | 2003-02-28 | F | Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| CA2464690A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| AT411852B (de) | 2002-02-12 | 2004-06-25 | Didosyan Yuri S Dr | Verfahren und vorrichtung zur änderung des polarisationszustandes von licht mit einem magnetisch einachsigen kristall |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| CA2622441A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| WO2007107563A2 (en) | 2006-03-20 | 2007-09-27 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| US8313924B2 (en) | 2006-08-01 | 2012-11-20 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| AU2007322265B2 (en) * | 2006-11-07 | 2013-06-20 | Merck Sharp & Dohme Corp. | Antagonists of PCSK9 |
| EP2083859A4 (en) * | 2006-11-07 | 2010-11-24 | Merck Sharp & Dohme | PCSK9 ANTAGONISTS |
| US20100233177A1 (en) * | 2007-04-13 | 2010-09-16 | David Langdon Yowe | Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| ES2346178T3 (es) | 2007-07-31 | 2015-11-02 | Affibody Ab | Nuevas composiciones, procedimientos y usos de unión de la albúmina |
| HUE043835T2 (hu) * | 2010-06-08 | 2019-09-30 | Pieris Pharmaceuticals Gmbh | IL-4 receptor-alfát kötõ könny-lipokalin muteinek |
| ES2540114T3 (es) | 2010-07-09 | 2015-07-08 | Affibody Ab | Polipéptidos |
| EP2802341B1 (en) * | 2012-01-09 | 2019-03-06 | Pieris Pharmaceuticals GmbH | Methods for preventing, treating or diagnosing disorders |
| WO2014140210A1 (en) | 2013-03-14 | 2014-09-18 | Pieris Ag | Novel binding proteins for pcsk9 |
-
2014
- 2014-03-13 WO PCT/EP2014/055013 patent/WO2014140210A1/en not_active Ceased
- 2014-03-13 RU RU2015142437A patent/RU2015142437A/ru not_active Application Discontinuation
- 2014-03-13 BR BR112015021681A patent/BR112015021681A2/pt not_active Application Discontinuation
- 2014-03-13 JP JP2015562159A patent/JP6619650B2/ja not_active Expired - Fee Related
- 2014-03-13 SG SG11201505856TA patent/SG11201505856TA/en unknown
- 2014-03-13 AU AU2014230460A patent/AU2014230460B2/en not_active Ceased
- 2014-03-13 MX MX2015012420A patent/MX2015012420A/es unknown
- 2014-03-13 CN CN201480012827.2A patent/CN105246503A/zh active Pending
- 2014-03-13 EP EP14716250.7A patent/EP2968490A1/en not_active Withdrawn
- 2014-03-13 HK HK16101229.3A patent/HK1213194A1/zh unknown
- 2014-03-13 KR KR1020157028381A patent/KR20150131151A/ko not_active Ceased
- 2014-03-13 CA CA2905186A patent/CA2905186A1/en not_active Abandoned
- 2014-03-13 US US14/208,629 patent/US9150629B2/en active Active
-
2015
- 2015-07-30 PH PH12015501687A patent/PH12015501687A1/en unknown
- 2015-08-28 US US14/839,222 patent/US9598476B2/en not_active Expired - Fee Related
- 2015-09-08 IL IL241329A patent/IL241329A0/en unknown
-
2017
- 2017-02-28 US US15/445,066 patent/US20170173112A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6619650B2 (ja) | 2019-12-11 |
| HK1213194A1 (zh) | 2016-06-30 |
| US9150629B2 (en) | 2015-10-06 |
| CN105246503A (zh) | 2016-01-13 |
| WO2014140210A1 (en) | 2014-09-18 |
| AU2014230460B2 (en) | 2018-04-05 |
| JP2016519051A (ja) | 2016-06-30 |
| PH12015501687A1 (en) | 2015-10-19 |
| IL241329A0 (en) | 2015-11-30 |
| CA2905186A1 (en) | 2014-09-18 |
| US9598476B2 (en) | 2017-03-21 |
| US20160024161A1 (en) | 2016-01-28 |
| BR112015021681A2 (pt) | 2017-11-14 |
| KR20150131151A (ko) | 2015-11-24 |
| EP2968490A1 (en) | 2016-01-20 |
| MX2015012420A (es) | 2016-06-02 |
| AU2014230460A1 (en) | 2015-09-10 |
| SG11201505856TA (en) | 2015-08-28 |
| US20170173112A1 (en) | 2017-06-22 |
| US20140288008A1 (en) | 2014-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015142437A (ru) | Новые связывающие белки для pcsk9 | |
| JP2016519051A5 (enExample) | ||
| Bellingham et al. | Self-aggregation characteristics of recombinantly expressed human elastin polypeptides | |
| RU2012150766A (ru) | Мутеины липокалина слезы, связывающие альфа il-4 r | |
| KR102236829B1 (ko) | 헵시딘 유사체 및 이의 용도 | |
| JP2018532372A5 (enExample) | ||
| RU2015137158A (ru) | МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2,hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ | |
| JP2018515084A5 (enExample) | ||
| EP3233902B1 (en) | Antifibrotic activity of gas6 inhibitor | |
| RU2012151205A (ru) | Модифицированные связывающие белки, ингибирующие взаимодействие vegf-a рецептора | |
| JP2013537400A5 (enExample) | ||
| AU2014257123A1 (en) | Interleukin-10 compositions and uses thereof | |
| JPH06508742A (ja) | 組換えトロンビンレセプターおよびそれに関連した薬剤 | |
| JP2018519802A5 (enExample) | ||
| RU2016149596A (ru) | Новые полипептиды со специфическим связыванием и пути их применения | |
| RU2017135605A (ru) | Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3) | |
| US20220220458A1 (en) | Modified AXL Peptides and Their Use in Inhibition of AXL Signaling in Anti-Metastatic Therapy | |
| RU2019122482A (ru) | Мутеины липокалина с аффинностью связывания в отношении lag-3 | |
| JP2020505948A5 (enExample) | ||
| JP2017502003A (ja) | プロテアーゼ耐性ペプチド | |
| Or et al. | Improvements in the minimum binding sequence of C5a: examination of His-67 | |
| Xie et al. | Agkihpin, a novel SVTLE from Gloydius halys Pallas, promotes platelet aggregation in vitro and inhibits thrombus formation in vivo in murine models of thrombosis | |
| JP2022530776A (ja) | リジルオキシダーゼのペプチドを含む組成物及びその使用 | |
| CN112969477B (zh) | 改善肽的血液动力学的方法 | |
| Qiang et al. | Discovery of a Novel Cysteine Framework XXIV Conotoxin from Conus Striatus, S24a, with Potential Analgesic Activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190322 |